title: [Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy].
abstract: A 63-year-old male presented with fever and general malaise in June 2004. On admission hepatosplenomegaly was apparent, but without lymphadenopathy. The laboratory examination revealed pancytopenia and increased levels of lactate dehydrogenase, direct bilirubin and soluble interleukin-2 receptor. Histological analysis of the bone marrow biopsy specimen demonstrated proliferation of atypical lymphoid cells positive for CD20 in the small capillaries, leading to the diagnosis of the Asian variant of intravascular large B-cell lymphoma (AIVL). The presence of rearrangement of the immunoglobulin gene confirmed the diagnosis. The patient responded well to CHOP therapy followed by seven courses of rituximab-combined CHOP therapy and has remained in complete remission up to the present. This case implies that bone marrow biopsy could be a useful examination for diagnosing AIVL and that rituximab-combinedchemotherapy could improve survival in patients with the disease.
authors.affiliation: Department of Hematology, Dokkyo Medical University School of Medicine.
authors.forename: Jiro
authors.initials: J
authors.lastname: Tadokoro
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Katsuya
authors.initials: K
authors.lastname: Tokita
authors.forename: Hisako
authors.initials: H
authors.lastname: Iso
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Maki
authors.forename: Ko
authors.initials: K
authors.lastname: Sasaki
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D044466:Asian People; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D019043:Vascular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone